Top Growth Stocks To Buy For 2019

Seven years after the end of the worst financial crisis since the Great Depression, the U.S. economy continues to lead the developed world. Gross domestic product in the U.S. has been rising only about 2% annually (compared with a more normal 3%), but the economies of most other major nations are at or just above stall speed.

See Also: 4 Best Cheap Funds to Invest in Now

Will we ever get back to normal global growth? Probably, given time, but a return to the good old days is still a ways in the future.

Meantime, efforts by central bankers to light a fire under the global economy have pushed down bond yields to ridiculously low levels. Until growth picks up, those yields should stay artificially low. Citing concerns over sluggish employment growth, the Federal Reserve once again opted to leave rates unchanged at its just-concluded June meeting.

Top Growth Stocks To Buy For 2019: Nuveen New York Dividend Advantage Municipal Fund(NAN)

Advisors’ Opinion:

  • [By Shane Hupp]

    Nuveen New York Dividend Advntg Mncpl Fd (NYSE:NAN) announced a monthly dividend on Tuesday, October 2nd, Wall Street Journal reports. Investors of record on Monday, October 15th will be given a dividend of 0.048 per share by the financial services provider on Thursday, November 1st. This represents a $0.58 annualized dividend and a yield of 4.69%. The ex-dividend date is Friday, October 12th.

Top Growth Stocks To Buy For 2019: Gerdau S.A.(GGB)

Advisors’ Opinion:

  • [By Max Byerly]

    Gerdau (NYSE:GGB) fell 7.6% on Tuesday . The stock traded as low as $3.99 and last traded at $4.00. 20,132,700 shares were traded during mid-day trading, an increase of 80% from the average session volume of 11,155,967 shares. The stock had previously closed at $4.33.

  • [By Logan Wallace]

    Shares of Gerdau SA (NYSE:GGB) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $4.00.

  • [By Shane Hupp]

    AMG Funds LLC lessened its stake in Gerdau (NYSE:GGB) by 12.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 256,979 shares of the basic materials company’s stock after selling 35,501 shares during the quarter. AMG Funds LLC’s holdings in Gerdau were worth $1,198,000 at the end of the most recent reporting period.

Top Growth Stocks To Buy For 2019: Cross Country Healthcare, Inc.(CCRN)

Advisors’ Opinion:

  • [By ]

    Activist investor Glenn Welling of Engaged Capital LLC, the insurgent investor agitating for changes at TiVo, Rent-a-Center, on Tuesday, May 15, revealed new positions in Aratana Therapeutics Inc. (PETX) , Cross Country Healthcare Inc. (CCRN)  and Finisar Corp. (FNSR)

  • [By Max Byerly]

    ValuEngine upgraded shares of Cross Country Healthcare (NASDAQ:CCRN) from a strong sell rating to a sell rating in a report issued on Thursday.

    Several other brokerages have also commented on CCRN. Lake Street Capital lowered shares of Cross Country Healthcare from a buy rating to a hold rating and dropped their price target for the stock from $16.00 to $11.00 in a research report on Thursday, May 3rd. Barrington Research reaffirmed a buy rating and set a $15.00 price target on shares of Cross Country Healthcare in a research report on Tuesday, May 22nd. Zacks Investment Research lowered shares of Cross Country Healthcare from a hold rating to a sell rating in a research report on Tuesday, July 10th. Credit Suisse Group dropped their price target on shares of Cross Country Healthcare from $11.50 to $9.00 and set a neutral rating for the company in a research report on Thursday, August 2nd. Finally, BMO Capital Markets lowered shares of Cross Country Healthcare from an outperform rating to a market perform rating and set a $13.00 price target for the company. in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. Cross Country Healthcare currently has a consensus rating of Hold and an average target price of $13.14.

  • [By Stephan Byrd]

    American International Group Inc. trimmed its stake in shares of Cross Country Healthcare, Inc. (NASDAQ:CCRN) by 20.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,638 shares of the business services provider’s stock after selling 5,648 shares during the period. American International Group Inc. owned about 0.06% of Cross Country Healthcare worth $252,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    BidaskClub lowered shares of Cross Country Healthcare (NASDAQ:CCRN) from a buy rating to a hold rating in a research note released on Thursday morning.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Cross Country Healthcare (CCRN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *